Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Megaloblastic anemia caused by vitamin B-12 deficiency due to impaired absorption. The impaired absorption of vitamin B-12 is secondary to atrophic gastritis and loss of gastric parietal cells.
Features include: Malabsorption of Vitamin B12 and Megaloblastic anemia.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Digestive system | 1 | Malabsorption of Vitamin B12 |
Blood and immune system | 1 | Megaloblastic anemia |
Biomarker and diagnostic research for pernicious anemia has been reported in the published literature.
1 FDA-approved treatment is available for pernicious anemia, including CYANOCOBALAMIN (NASCOBAL, approved 2005).
Brand Name | Generic Name | Mechanism | Approved | Market Status |
|---|---|---|---|---|
NASCOBAL | CYANOCOBALAMIN | — | 2005 | Available |
1 clinical trial registered. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.
151 publications have been identified in PubMed for pernicious anemia. Kisho has analyzed 76 by research type. Research spans Case Report / Case Series (43%), Review / Meta-Analysis (28%), and Epidemiology / Natural History (21%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 33 |
Data assembled from 7 of 12 sources · Last updated Sep 20, 2026, 6:27 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
1 trial found
Research summaries | 21 | 28% |
Disease patterns and progression | 16 | 21% |
Testing and diagnosis research | 4 | 5% |
Other research | 2 | 3% |
Lacombe V (2026). [PMID: 40955495](https://pubmed.ncbi.nlm.nih.gov/40955495/). *Clin Chem Lab Med*. [Epidemiology / Natural History]
Rohner A (2026). [PMID: 41993099](https://pubmed.ncbi.nlm.nih.gov/41993099/). *Case Rep Hematol*. [Case Report / Case Series]
Mclaughlin TB (2026). [PMID: 41915627](https://pubmed.ncbi.nlm.nih.gov/41915627/). *Am J Case Rep*. [Case Report / Case Series]
Ahn YH (2026). [PMID: 42087799](https://pubmed.ncbi.nlm.nih.gov/42087799/). *Gut Liver*. [Review / Meta-Analysis]
Wang J (2026). [PMID: 41589618](https://pubmed.ncbi.nlm.nih.gov/41589618/). *Autoimmunity*. [Review / Meta-Analysis]
Sugimoto T (2026). [PMID: 42106905](https://pubmed.ncbi.nlm.nih.gov/42106905/). *Am J Case Rep*. [Case Report / Case Series]
Varela-Chinchilla CD (2026). [PMID: 31613538](https://pubmed.ncbi.nlm.nih.gov/31613538/). *Unknown Journal*. [Diagnostic / Biomarker]
Muranova A (2026). [PMID: 34424651](https://pubmed.ncbi.nlm.nih.gov/34424651/). *Unknown Journal*. [Diagnostic / Biomarker]
Thannir S (2026). [PMID: 42027074](https://pubmed.ncbi.nlm.nih.gov/42027074/). *J Investig Med High Impact Case Rep*. [Case Report / Case Series]
Salimiaghdam N (2025). [PMID: 40109835](https://pubmed.ncbi.nlm.nih.gov/40109835/). *Cureus*. [Case Report / Case Series]